Agile Therapeutics (NASDAQ:AGRX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Friday. They presently have a $4.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 412.69% from the company’s previous close.
The analysts wrote, “We don’t think this should even be required, as Twirla is a different product than Xulane/Ortho Evra, not a generic copy, so its benefit-risk profile—which we think is better—should stand on its own merits. Nevertheless, the minutes were consistent with our expectation for a straightforward two-week crossover study (one week on each patch) to show that Twirla adhesion is non-inferior (NI) to Xulane. The company has not disclosed the specific NI margin that the agency is requiring, but the planned sample size of only n=80 suggests to us that the FDA has given them some NI breathing room. We are confident in success based on Phase 3 adhesion data (more below). Agile already had the study teed up and ready to go, and has immediately initiated it with a dermatology-specialized CRO, TKL Research.””
Separately, Maxim Group initiated coverage on Agile Therapeutics in a report on Thursday, November 29th. They issued a “buy” rating and a $3.00 target price on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Agile Therapeutics presently has an average rating of “Buy” and an average target price of $3.33.
NASDAQ:AGRX traded down $0.01 on Friday, hitting $0.78. The stock had a trading volume of 200,806 shares, compared to its average volume of 233,841. The firm has a market cap of $27.24 million, a P/E ratio of -0.86 and a beta of -0.16. Agile Therapeutics has a 52 week low of $0.23 and a 52 week high of $3.92.
Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.04. On average, equities research analysts expect that Agile Therapeutics will post -0.59 earnings per share for the current year.
A hedge fund recently raised its stake in Agile Therapeutics stock. Renaissance Technologies LLC lifted its holdings in shares of Agile Therapeutics Inc (NASDAQ:AGRX) by 76.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 792,990 shares of the specialty pharmaceutical company’s stock after acquiring an additional 343,290 shares during the quarter. Renaissance Technologies LLC owned 2.31% of Agile Therapeutics worth $392,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 42.02% of the company’s stock.
About Agile Therapeutics
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Featured Article: Average Daily Trade Volume – What It Means In Stock Trading
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.